Clinical Trial Update: Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This is a completed Phase 2 trial update evaluating Erlotinib in combination with Celecoxib for patients with Stage IIIB or Stage IV recurrent non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• CELEBREX (Celecoxib)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED